CA2503439A1 - Process for preparing (r)-salbutamol - Google Patents
Process for preparing (r)-salbutamol Download PDFInfo
- Publication number
- CA2503439A1 CA2503439A1 CA002503439A CA2503439A CA2503439A1 CA 2503439 A1 CA2503439 A1 CA 2503439A1 CA 002503439 A CA002503439 A CA 002503439A CA 2503439 A CA2503439 A CA 2503439A CA 2503439 A1 CA2503439 A1 CA 2503439A1
- Authority
- CA
- Canada
- Prior art keywords
- process according
- asymmetric hydrogenation
- carried out
- salbutamone
- catalyst
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention relates to an improved method for producing levosalbutamol or the pharmacologically acceptable salts thereof on an industrial scale by using asymmetric hydration as a key step and, optionally, a special sequence of successive steps, rhodium being used as a catalyst while a chiral, ambident phosphine ligand such as (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphenyl-phosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine is used as a catalyst system.
Description
1/1404-prio 1 / 12 1 Boehringer Ingelheim Pharma KG
82421 pri Process for preparing (R)-salbutamol The present invention relates to an improved process for preparing (R)-salbutamol by rhodium-catalysed asymmetrical hydrogenation on an industrial scale.
Technical background to the invention (R)-Salbutamol, levosalbutamol or (R)-albuterol is a-[[(1,1-dimethylethyl)-amino)methyl-4-hydroxy-1,3-benzenedimethanol, belongs to the [i-2-agonists used pharmaceutically as bronchodilators and is of considerable commercial interest. The chemical structure of the chiral a-aminoalcohol (R)-salbutamol is shown in formula I:
HO
H H3C~
C
\ , CHz N~ wCHs H
HO f CI) HO~CHZ
Prior art The methods of preparing (R)-salbutamol known from the prior art include the racemate cleaving of racemic salbutamol using di-toluyltartaric acid, e.g.
according to US Patent US 5,399,765. In addition, International Patent Application WO 95/29146 proposes the preparation of (R)-salbutamol starting from corresponding alpha-iminoketone by enantioselective reduction with boranes in the presence of a chiral oxaborazole catalyst.
However, the processes described in the prior art are not suitable for preparing (R)-salbutamol on an industrial scale as half the valuable starting product is lost during the racemate cleaving and large amounts of the oxaborazole catalyst, which is difficult to obtain, have to be used during the enantioselective reduction.
I/1404-prio 2 / I2 2 Boehringer Ingelheim Pharma KG
One of the primary objectives of the present invention is to develop a process by means of which (R)-salbutamol can be prepared with a high degree of optical and chemical purity. This is intended, for example, to minimise the danger of drugs which contain (R)-salbutamol as active substance being contaminated with the unwanted D-enantiomer.
Another aim of the invention is to develop a process by means of which (R)-salbutamol can easily be prepared in substantially enantiomerically pure form from starting materials which are easily obtained.
Another aim of the invention is to prepare (R)-salbutamol by means of a stereoselective process in order to avoid reaction steps in which chiral intermediate compounds or the chiral end product (R)-salbutamol is obtained as a racemate in a similar amount to the corresponding antipode.
Surprisingly it has now been found that (R)-salbutamol can be obtained on an industrial scale in very good yields and with good optical purity if salbutamone is subjected to asymmetric hydrogenation in the presence of rhodium and a chiral, bidentate phosphine ligand as catalyst system.
Description of the invention The present invention relates to a process for preparing fevosalbutamol or (R)-salbutamol or the pharmacologically acceptable salts thereof starting from prochiral salbutamone as educt, in which salbutamone is subjected to asymmetric hydrogenation in the presence of rhodium and a chiral bidentate phosphine figand (PP*), particularly (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine, as catalyst system, and the levosalbutamol obtained is optionally converted into a salt with an acid.
1/1404-prio 3 / 12 3 Boehringer Ingelheim Pharma KG
In a preferred process the asymmetric hydrogenation is carried out in a temperature range from 20°C to 100°C, preferably from 40°C to 60°C, particularly from 45°C to 55°C.
Also preferred is a process in which the asymmetric hydrogenation is carried out under a pressure of mare than 1 bar to 100 bar , preferably under a pressure of 10 bar to 50 bar, particularly at about 20 bar.
The reaction media used may be both protic solvents - such as e.g. alcohols and/or water or aprotic polar solvents such as e.g. ethers and/or amides or lactams and/or mixtures thereof. Water may optionally be added to all the solvents. The protic solvents used are preferably branched or unbranched C~-C8 alkanols. Particularly preferably, lower alcohols such as methanol, ethanol, n-propanol and isopropanol or mixtures thereof are used. Methanol is particularly preferably used as the reaction medium, while the methanol or the other alcohols or solvents may optionally contain water. Suitable aprotic solvents are polar ethers such as for example tetrahydrofuran or dimethoxyethylether or amides such as for example dimethylformamide, or lactams such as for example N-methylpyrrolidone. Preferably, solvents with a slight tendency to flammability are used.
The reaction is preferably carried out in the presence of a base. The base used may be an organic base or an inorganic bases both in solid form and also in the form of solutions, e.g. aqueous solutions. Suitable inorganic bases are basically reacting alkali metal salts or alkali metal hydroxides.
Preferably, alkali metal hydrogen carbonates or alkali metal carbonates are used in addition to alkali metal hydroxides. Most preferably, Na2C03, K2COg, LiOH, NaOH, KOH or NaHCOg is used.
Suitable organic bases are tertiary amines, particularly tertiary alkyl-amines, tertiary alkyl-aryl-amines or pyridines. Preferably trialkylamines with branched or unbranched C, - C5-alkyl groups are used. Triethylamine or diisopropylethylamine have proved particularly preferable for example. If 1/1404-prio 4 / 12 4 Boehringer Ingelheim Pharma KG
desired the reaction may also be carried out in the presence of basic polymers with e.g. tertiary amino functions.
Preferred methods are those wherein salbutamone is used in a molar ratio to the rhodium catalyst of from 500:1 to 100000:1, preferably from 750:1 to 20000:1 during asymmetric hydrogenation.
With a molar ratio of catalyst to substrate of about 1:1000 (R)-salbutamol is obtained in an optical purity of 70 % ee by the process according to the invention starting from salbutamone (reaction plan 1 ). By converting the salbutamol (I) into an acid addition salt and subsequently precipitating it from an ammonia-methanol-water mixture the optical purity can be further increased in a simple and remarkable manner.
It has also been found that, in contrast to the teaching of WO 95/29146, there is no need to have a molar ratio of catalyst to substrate of about 1:10, as disclosed therein, for the asymmetric reduction in order to obtain good yields or high optical purity. In the process according to the invention this ratio can be drastically lowered by a factor of 10 to 1000. In spite of this significant reduction in the amount of catalyst the (R)-salbutamol resulting from the asymmetric hydrogenation is still obtained in a significantly higher optical yields than by the process known from the prior art. The reduction in the amount of catalyst makes it much easier to purify the product.
By reducing the amount of catalyst and using the commercially favourable salbutamone as educt the costs of producing (R)-salbutamol can be reduced substantially by the new process.
The salbutamone to be used as starting product is obtained by hydrogenation of N-benzylsalbutamone, which may be prepared by brominating 4-acetyloxy-3-acetyloxymethylbenzophenone and subsequently reacting with tent butyl-benzylamine (TBBA) according to the following reaction plan:
1/1404-prio 5 / 12 5 Boehringer Ingelheim Pharma KG
Reaction~lan O
1) Br2 2) TBBA
O HO
/~O
HZ / Pd-C
N
HZ ~H
Rh-PP*
HO HO
(I) In addition, the space-time yield can be improved over that of the prior art using the new process. It is particularly advantageous for preparing (R)-salbutamol on an industrial scale from the point of view of costs and safety.
Finally, it is possible using the process according to the invention to do away with the protection of the phenolic hydroxyl group in salbutamone and still successfully react it to obtain chiral (R)-salbutamol using asymmetric hydrogenation with one of the catalyst systems according to the invention.
According to the invention the catalyst used is [Rh(COD)Clj 2, where COD
denotes a cyclooctadienyl group, and a chiral, bidentate phosphine ligand (PP'~). Preferably (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonylpyrrolidine (RR-MCCPM) is used as catalyst.
1/1404-prio 6 / 12 6 Boehringer Ingelheim Pharma KG
The preparation of this catalyst is known from the prior art [EP-A-0 251 164, EP-A-0 336 123]. The catalyst may also be bound to the polymer, e.g. by having the chiral ligand (2R, 4R)-4-dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl) pyrrolidine bound to a polymer via the phenyl groups, for example. The use of such polymer-bound ligands does not totally rule out the simultaneous use of non-polymer-bound ligands. Such polymer-bound catalysts are particularly advantageous for simple purification of the product.
The catalyst is either used as a prefabricated, oxygen-free solution of [Rh(COD)CIJZ and ligand or prepared in situ from [Rh(COD)CI]2 and ligand in the presence of salbutamone without oxygen in a protective gas atmosphere or hydrogen atmosphere.
The hydrogenation is generally carried out without oxygen, conveniently under inert gas, preferably under a hydrogen atmosphere. However, it is not essential to the reaction that the hydrogen for the hydrogenation should be capable of being taken from the atmospheric gas above the reaction mixture.
The hydrogen may also be produced in solution in situ from suitable hydrogen sources. Such hydrogen sources include e.g. ammonium formate, formic acid and other formates, hydrazines in the presence of metal ions such as Fe2+lFe3+ and other hydrogen sources known from the prior art.
The reaction time for the asymmetric hydrogenation to be completed is generally between 2 and 48 hours, preferably between 4 and 36 hours, and particularly preferably about 23 hours.
The reaction of N-benzyl-salbutamone to obtain salbutamone is carried out by palladium-catalysed hydrogenating debenzylation. The reaction mixture from the asymmetric hydrogenation may be combined with a palladium catalyst without any further working up.
1/1404-prio 7 / 12 7 Boehringer Ingelheim Pharma KG
In this method benzylsalbutamone is combined with activated charcoal and a palladium chloride solution and hydrogenated under a pressure of more than 1 to 5 bar, preferably 2 - 3 bar. The further working up is carried out according to methods known from the literature.
The process according to the invention will now be illustrated by the Examples that follow. The skilled man will be aware that the examples are provided solely as an illustration and are not to be viewed as restrictive.
Examples Example 1 Benzylsalbutamone 900 g of 4-acetyloxy-3-acetyloxymethylbenzophenone are placed in 6 I of suitable solvent. After the addition of 614 g bromine the mixture is refluxed for a further 30 minutes and cooled. After the addition of 1153 g of tert butylbenzylamine the mixture is refluxed for another 20-25 h. After the precipitate has been filtered the organic phase is extracted with hydrochloric acid and the product is crystallised. 806 g of benzylsalbutamone are obtained.
Example 2 Salbutamone 36.4 g of benzylsalbutamone are taken up in 110 ml of water and stirred for 2.5 with 1 g of 10% Pd/C at 2 bar hydrogen pressure and at 40 °C. The precipitate is dissolved with methanol. The solution is filtered through Celite and evaporated down until crystallisation starts. It is cooled overnight to ambient temperature and the crystals are filtered off. After washing with a little cold water and drying overnight at 50 °C in vacuo, salbutamone is obtained in a 92% yield.
1/1404-prio 8 / 12 8 Boehringer Ingelheim Pharma KG
Example 3 (R)-(-)-salbutamol g of salbutamone are dissolved in 100 ml of methanol (degassed) and 0.13 ml of triethylamine. 4.7 mg of (RhCODCI)2 and 10 mg of (2R, 4R)-4-dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl) pyrrolidine (as a toluenic solution) are added and the mixture is stirred for 23 h at 50 °C and 20 bar hydrogen pressure. The reaction solution is concentrated by rotary evaporation and the residue is recrystallised from ethanol. The salbutamol is obtained in a yield of 90% in an optical purity of approx. 70°lo e.e.
82421 pri Process for preparing (R)-salbutamol The present invention relates to an improved process for preparing (R)-salbutamol by rhodium-catalysed asymmetrical hydrogenation on an industrial scale.
Technical background to the invention (R)-Salbutamol, levosalbutamol or (R)-albuterol is a-[[(1,1-dimethylethyl)-amino)methyl-4-hydroxy-1,3-benzenedimethanol, belongs to the [i-2-agonists used pharmaceutically as bronchodilators and is of considerable commercial interest. The chemical structure of the chiral a-aminoalcohol (R)-salbutamol is shown in formula I:
HO
H H3C~
C
\ , CHz N~ wCHs H
HO f CI) HO~CHZ
Prior art The methods of preparing (R)-salbutamol known from the prior art include the racemate cleaving of racemic salbutamol using di-toluyltartaric acid, e.g.
according to US Patent US 5,399,765. In addition, International Patent Application WO 95/29146 proposes the preparation of (R)-salbutamol starting from corresponding alpha-iminoketone by enantioselective reduction with boranes in the presence of a chiral oxaborazole catalyst.
However, the processes described in the prior art are not suitable for preparing (R)-salbutamol on an industrial scale as half the valuable starting product is lost during the racemate cleaving and large amounts of the oxaborazole catalyst, which is difficult to obtain, have to be used during the enantioselective reduction.
I/1404-prio 2 / I2 2 Boehringer Ingelheim Pharma KG
One of the primary objectives of the present invention is to develop a process by means of which (R)-salbutamol can be prepared with a high degree of optical and chemical purity. This is intended, for example, to minimise the danger of drugs which contain (R)-salbutamol as active substance being contaminated with the unwanted D-enantiomer.
Another aim of the invention is to develop a process by means of which (R)-salbutamol can easily be prepared in substantially enantiomerically pure form from starting materials which are easily obtained.
Another aim of the invention is to prepare (R)-salbutamol by means of a stereoselective process in order to avoid reaction steps in which chiral intermediate compounds or the chiral end product (R)-salbutamol is obtained as a racemate in a similar amount to the corresponding antipode.
Surprisingly it has now been found that (R)-salbutamol can be obtained on an industrial scale in very good yields and with good optical purity if salbutamone is subjected to asymmetric hydrogenation in the presence of rhodium and a chiral, bidentate phosphine ligand as catalyst system.
Description of the invention The present invention relates to a process for preparing fevosalbutamol or (R)-salbutamol or the pharmacologically acceptable salts thereof starting from prochiral salbutamone as educt, in which salbutamone is subjected to asymmetric hydrogenation in the presence of rhodium and a chiral bidentate phosphine figand (PP*), particularly (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine, as catalyst system, and the levosalbutamol obtained is optionally converted into a salt with an acid.
1/1404-prio 3 / 12 3 Boehringer Ingelheim Pharma KG
In a preferred process the asymmetric hydrogenation is carried out in a temperature range from 20°C to 100°C, preferably from 40°C to 60°C, particularly from 45°C to 55°C.
Also preferred is a process in which the asymmetric hydrogenation is carried out under a pressure of mare than 1 bar to 100 bar , preferably under a pressure of 10 bar to 50 bar, particularly at about 20 bar.
The reaction media used may be both protic solvents - such as e.g. alcohols and/or water or aprotic polar solvents such as e.g. ethers and/or amides or lactams and/or mixtures thereof. Water may optionally be added to all the solvents. The protic solvents used are preferably branched or unbranched C~-C8 alkanols. Particularly preferably, lower alcohols such as methanol, ethanol, n-propanol and isopropanol or mixtures thereof are used. Methanol is particularly preferably used as the reaction medium, while the methanol or the other alcohols or solvents may optionally contain water. Suitable aprotic solvents are polar ethers such as for example tetrahydrofuran or dimethoxyethylether or amides such as for example dimethylformamide, or lactams such as for example N-methylpyrrolidone. Preferably, solvents with a slight tendency to flammability are used.
The reaction is preferably carried out in the presence of a base. The base used may be an organic base or an inorganic bases both in solid form and also in the form of solutions, e.g. aqueous solutions. Suitable inorganic bases are basically reacting alkali metal salts or alkali metal hydroxides.
Preferably, alkali metal hydrogen carbonates or alkali metal carbonates are used in addition to alkali metal hydroxides. Most preferably, Na2C03, K2COg, LiOH, NaOH, KOH or NaHCOg is used.
Suitable organic bases are tertiary amines, particularly tertiary alkyl-amines, tertiary alkyl-aryl-amines or pyridines. Preferably trialkylamines with branched or unbranched C, - C5-alkyl groups are used. Triethylamine or diisopropylethylamine have proved particularly preferable for example. If 1/1404-prio 4 / 12 4 Boehringer Ingelheim Pharma KG
desired the reaction may also be carried out in the presence of basic polymers with e.g. tertiary amino functions.
Preferred methods are those wherein salbutamone is used in a molar ratio to the rhodium catalyst of from 500:1 to 100000:1, preferably from 750:1 to 20000:1 during asymmetric hydrogenation.
With a molar ratio of catalyst to substrate of about 1:1000 (R)-salbutamol is obtained in an optical purity of 70 % ee by the process according to the invention starting from salbutamone (reaction plan 1 ). By converting the salbutamol (I) into an acid addition salt and subsequently precipitating it from an ammonia-methanol-water mixture the optical purity can be further increased in a simple and remarkable manner.
It has also been found that, in contrast to the teaching of WO 95/29146, there is no need to have a molar ratio of catalyst to substrate of about 1:10, as disclosed therein, for the asymmetric reduction in order to obtain good yields or high optical purity. In the process according to the invention this ratio can be drastically lowered by a factor of 10 to 1000. In spite of this significant reduction in the amount of catalyst the (R)-salbutamol resulting from the asymmetric hydrogenation is still obtained in a significantly higher optical yields than by the process known from the prior art. The reduction in the amount of catalyst makes it much easier to purify the product.
By reducing the amount of catalyst and using the commercially favourable salbutamone as educt the costs of producing (R)-salbutamol can be reduced substantially by the new process.
The salbutamone to be used as starting product is obtained by hydrogenation of N-benzylsalbutamone, which may be prepared by brominating 4-acetyloxy-3-acetyloxymethylbenzophenone and subsequently reacting with tent butyl-benzylamine (TBBA) according to the following reaction plan:
1/1404-prio 5 / 12 5 Boehringer Ingelheim Pharma KG
Reaction~lan O
1) Br2 2) TBBA
O HO
/~O
HZ / Pd-C
N
HZ ~H
Rh-PP*
HO HO
(I) In addition, the space-time yield can be improved over that of the prior art using the new process. It is particularly advantageous for preparing (R)-salbutamol on an industrial scale from the point of view of costs and safety.
Finally, it is possible using the process according to the invention to do away with the protection of the phenolic hydroxyl group in salbutamone and still successfully react it to obtain chiral (R)-salbutamol using asymmetric hydrogenation with one of the catalyst systems according to the invention.
According to the invention the catalyst used is [Rh(COD)Clj 2, where COD
denotes a cyclooctadienyl group, and a chiral, bidentate phosphine ligand (PP'~). Preferably (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonylpyrrolidine (RR-MCCPM) is used as catalyst.
1/1404-prio 6 / 12 6 Boehringer Ingelheim Pharma KG
The preparation of this catalyst is known from the prior art [EP-A-0 251 164, EP-A-0 336 123]. The catalyst may also be bound to the polymer, e.g. by having the chiral ligand (2R, 4R)-4-dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl) pyrrolidine bound to a polymer via the phenyl groups, for example. The use of such polymer-bound ligands does not totally rule out the simultaneous use of non-polymer-bound ligands. Such polymer-bound catalysts are particularly advantageous for simple purification of the product.
The catalyst is either used as a prefabricated, oxygen-free solution of [Rh(COD)CIJZ and ligand or prepared in situ from [Rh(COD)CI]2 and ligand in the presence of salbutamone without oxygen in a protective gas atmosphere or hydrogen atmosphere.
The hydrogenation is generally carried out without oxygen, conveniently under inert gas, preferably under a hydrogen atmosphere. However, it is not essential to the reaction that the hydrogen for the hydrogenation should be capable of being taken from the atmospheric gas above the reaction mixture.
The hydrogen may also be produced in solution in situ from suitable hydrogen sources. Such hydrogen sources include e.g. ammonium formate, formic acid and other formates, hydrazines in the presence of metal ions such as Fe2+lFe3+ and other hydrogen sources known from the prior art.
The reaction time for the asymmetric hydrogenation to be completed is generally between 2 and 48 hours, preferably between 4 and 36 hours, and particularly preferably about 23 hours.
The reaction of N-benzyl-salbutamone to obtain salbutamone is carried out by palladium-catalysed hydrogenating debenzylation. The reaction mixture from the asymmetric hydrogenation may be combined with a palladium catalyst without any further working up.
1/1404-prio 7 / 12 7 Boehringer Ingelheim Pharma KG
In this method benzylsalbutamone is combined with activated charcoal and a palladium chloride solution and hydrogenated under a pressure of more than 1 to 5 bar, preferably 2 - 3 bar. The further working up is carried out according to methods known from the literature.
The process according to the invention will now be illustrated by the Examples that follow. The skilled man will be aware that the examples are provided solely as an illustration and are not to be viewed as restrictive.
Examples Example 1 Benzylsalbutamone 900 g of 4-acetyloxy-3-acetyloxymethylbenzophenone are placed in 6 I of suitable solvent. After the addition of 614 g bromine the mixture is refluxed for a further 30 minutes and cooled. After the addition of 1153 g of tert butylbenzylamine the mixture is refluxed for another 20-25 h. After the precipitate has been filtered the organic phase is extracted with hydrochloric acid and the product is crystallised. 806 g of benzylsalbutamone are obtained.
Example 2 Salbutamone 36.4 g of benzylsalbutamone are taken up in 110 ml of water and stirred for 2.5 with 1 g of 10% Pd/C at 2 bar hydrogen pressure and at 40 °C. The precipitate is dissolved with methanol. The solution is filtered through Celite and evaporated down until crystallisation starts. It is cooled overnight to ambient temperature and the crystals are filtered off. After washing with a little cold water and drying overnight at 50 °C in vacuo, salbutamone is obtained in a 92% yield.
1/1404-prio 8 / 12 8 Boehringer Ingelheim Pharma KG
Example 3 (R)-(-)-salbutamol g of salbutamone are dissolved in 100 ml of methanol (degassed) and 0.13 ml of triethylamine. 4.7 mg of (RhCODCI)2 and 10 mg of (2R, 4R)-4-dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl) pyrrolidine (as a toluenic solution) are added and the mixture is stirred for 23 h at 50 °C and 20 bar hydrogen pressure. The reaction solution is concentrated by rotary evaporation and the residue is recrystallised from ethanol. The salbutamol is obtained in a yield of 90% in an optical purity of approx. 70°lo e.e.
Claims (20)
1. Process for preparing levosalbutamol or the pharmacologically acceptable salts thereof starting from prochiral salbutamone as educt, characterised in that salbutamone is subjected to asymmetric hydrogenation in the presence of rhodium and a chiral bidentate phosphine ligand as catalyst system, and the levosalbutamol obtained is optionally converted into a salt with an acid.
2. Process according to claim 1, characterised in that the ligand is (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine.
3. Process according to claim 1, characterised in that the ligand is polymer-bound (2R, 4R)-4-(dicyclohexylphosphino)-2-(diphenylphosphino-methyl)-N-methyl-aminocarbonyl-pyrrolidine.
4. Process according to one of claims 1 to 3, characterised in that the asymmetric hydrogenation is carried out in a temperature range from 20°C to 100°C.
5. Process according to claim 4, characterised in that the asymmetric hydrogenation is carried out in a temperature range from 40°C to 60°C.
6. Process according to claim 5, characterised in that the asymmetric hydrogenation is carried out in a temperature range from 45°C to 55°C.
7. Process according to one of the preceding claims 1 to 6, characterised in that the asymmetric hydrogenation is carried out under a pressure of more than 1 bar to 100 bar , preferably under a pressure of 10 bar to 50 bar.
8. Process according to claim 7, characterised in that the asymmetric hydrogenation is carried out under a pressure of about 20 bar.
9. Process according to one of the preceding claims 1 to 8, characterised in that the asymmetric hydrogenation is carried out in a erotic solvent.
10. Process according to claim 9, characterised in that the asymmetric hydrogenation is carried out in a branched or unbranched C1 - C8-alkanol as solvent.
11. Process according to the preceding claim 10, characterised in that the asymmetric hydrogenation is carried out in methanol, ethanol, n propanol and/or isopropanol as solvent.
12. Process according to one of the preceding claims 9 to 11, characterised in that the solvent for the asymmetric hydrogenation contains water.
13. Process according to one of the preceding claims 1 to 12, characterised in that during asymmetric hydrogenation salbutamone is used in a molar ratio to the rhodium catalyst of from 500:1 to 100000:1, preferably from 750:1 to 20000:1.
14. Process according to claim 13, characterised in that the molar ratio of salbutamone to the rhodium catalyst during asymmetric hydrogenation is about 1000:1.
15. Process according to one of the preceding claims 1 to 14, characterised in that the rhodium catalyst for the asymmetric hydrogenation is used as a pre-prepared solution.
16. Process according to one of the preceding claims 1 to 14, characterised in that the rhodium catalyst for the asymmetric hydrogenation is produced in situ.
17. Process according to one of the preceding claims 1 to 16, characterised in that the asymmetric hydrogenation is carried out within a reaction time of 2 to 48 hours, preferably 4 to 36 hours.
18. Process according to claim 17, characterised in that the reaction time for the asymmetric hydrogenation is about 23 hours.
19. Process according to one of the preceding claims 1 to 18, characterised in that salbutamone is prepared starting from N-benzylsalbutamone by hydrogenation in the presence of a palladium catalyst.
20. Process for preparing levosalbutamol or the pharmacologically acceptable salts thereof, which comprises the following steps:
(a) brominating 4-acetyloxy-3-acetyloxymethylbenzophenone, (b) reacting the product obtained with N-tert-butyl-N-benzylamine, (c) hydrogenating the N-benzylsalbutamone obtained in the presence of a palladium catalyst, (d) hydrogenating the salbutamone obtained in the presence of rhodium and a chiral bidentate phosphine ligand, and (e) optionally treating it with an acid.
(a) brominating 4-acetyloxy-3-acetyloxymethylbenzophenone, (b) reacting the product obtained with N-tert-butyl-N-benzylamine, (c) hydrogenating the N-benzylsalbutamone obtained in the presence of a palladium catalyst, (d) hydrogenating the salbutamone obtained in the presence of rhodium and a chiral bidentate phosphine ligand, and (e) optionally treating it with an acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10249576.9 | 2002-10-24 | ||
| DE10249576A DE10249576B3 (en) | 2002-10-24 | 2002-10-24 | Preparation of levo-salbutamol, useful as bronchodilator, by asymmetrical catalytic hydrogenation of its ketone precursor in presence of rhodium and chiral phosphine |
| PCT/EP2003/011583 WO2004037767A1 (en) | 2002-10-24 | 2003-10-18 | Method for the production of (r)-salbutamol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2503439A1 true CA2503439A1 (en) | 2004-05-06 |
Family
ID=31984428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002503439A Abandoned CA2503439A1 (en) | 2002-10-24 | 2003-10-18 | Process for preparing (r)-salbutamol |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1585718B1 (en) |
| JP (1) | JP2006503884A (en) |
| CN (1) | CN1289465C (en) |
| AT (1) | ATE367372T1 (en) |
| AU (1) | AU2003282038A1 (en) |
| CA (1) | CA2503439A1 (en) |
| DE (2) | DE10249576B3 (en) |
| ES (1) | ES2290509T3 (en) |
| HK (1) | HK1084938A1 (en) |
| WO (1) | WO2004037767A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112500291A (en) * | 2020-12-14 | 2021-03-16 | 上海医药集团(本溪)北方药业有限公司 | Preparation and purification method of beta 2 receptor agonist intermediate |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004033313A1 (en) | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Process for the preparation of enantiomers 3-hydroxy-3-phenyl-propylamines |
| WO2007145203A1 (en) * | 2006-06-13 | 2007-12-21 | Daiichi Fine Chemical Co., Ltd. | Optically active 2-amino-1-(4-fluorophenyl)ethanol |
| CN103553941B (en) * | 2013-10-30 | 2015-02-18 | 新乡学院 | Method for preparing levalbuterol |
| CN108623486A (en) * | 2018-07-13 | 2018-10-09 | 重庆康刻尔制药有限公司 | A kind of preparation method of V hydrochloride of salbutamol intermediate |
| CN110963929B (en) * | 2019-11-26 | 2022-10-21 | 安徽恒星制药有限公司 | Preparation method of salbutamol hydrochloride suitable for industrial production |
| CN112062684B (en) * | 2020-09-15 | 2021-06-15 | 重庆康刻尔制药股份有限公司 | Method for purifying salbutamol intermediate IV |
| CN115286521B (en) * | 2022-07-11 | 2023-11-03 | 上海医药集团(本溪)北方药业有限公司 | Synthesis method of levosalbutamol hydrochloride |
| CN115073313B (en) * | 2022-08-24 | 2022-11-25 | 山东省食品药品检验研究院 | Method for synthesizing terbutaline sulfate impurity C |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1200886A (en) * | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| US5442118A (en) * | 1994-04-22 | 1995-08-15 | Sepracor, Inc. | Asymmetric synthesis of (R)- and (S)-arylethanolamines from iminoketones |
| DE19902229C2 (en) * | 1999-01-21 | 2000-11-02 | Boehringer Ingelheim Pharma | Process for the preparation of L-phenylephrine hydrochloride |
-
2002
- 2002-10-24 DE DE10249576A patent/DE10249576B3/en not_active Expired - Fee Related
-
2003
- 2003-10-18 CN CN200380101904.3A patent/CN1289465C/en not_active Expired - Fee Related
- 2003-10-18 ES ES03773653T patent/ES2290509T3/en not_active Expired - Lifetime
- 2003-10-18 JP JP2004545893A patent/JP2006503884A/en active Pending
- 2003-10-18 AU AU2003282038A patent/AU2003282038A1/en not_active Abandoned
- 2003-10-18 WO PCT/EP2003/011583 patent/WO2004037767A1/en active IP Right Grant
- 2003-10-18 EP EP03773653A patent/EP1585718B1/en not_active Expired - Lifetime
- 2003-10-18 CA CA002503439A patent/CA2503439A1/en not_active Abandoned
- 2003-10-18 DE DE50307735T patent/DE50307735D1/en not_active Expired - Lifetime
- 2003-10-18 AT AT03773653T patent/ATE367372T1/en not_active IP Right Cessation
-
2006
- 2006-04-28 HK HK06105082A patent/HK1084938A1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112500291A (en) * | 2020-12-14 | 2021-03-16 | 上海医药集团(本溪)北方药业有限公司 | Preparation and purification method of beta 2 receptor agonist intermediate |
Also Published As
| Publication number | Publication date |
|---|---|
| DE50307735D1 (en) | 2007-08-30 |
| EP1585718A1 (en) | 2005-10-19 |
| EP1585718B1 (en) | 2007-07-18 |
| HK1084938A1 (en) | 2006-08-11 |
| DE10249576B3 (en) | 2004-04-08 |
| AU2003282038A1 (en) | 2004-05-13 |
| ATE367372T1 (en) | 2007-08-15 |
| CN1705634A (en) | 2005-12-07 |
| CN1289465C (en) | 2006-12-13 |
| ES2290509T3 (en) | 2008-02-16 |
| JP2006503884A (en) | 2006-02-02 |
| WO2004037767A1 (en) | 2004-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7247750B2 (en) | Process for preparing (R)-salbutamol | |
| US6187956B1 (en) | Method for preparing of L-phenylephrine hydrochloride | |
| CA2603145A1 (en) | Process for preparing cinacalcet hydrochloride | |
| CA2556994A1 (en) | Method for producing n-alkyl-n-methyl-3-hydroxy-3-(2-thienyl)-propylamines | |
| CA2503439A1 (en) | Process for preparing (r)-salbutamol | |
| CA2381246C (en) | Process for preparing adrenaline | |
| US6653507B2 (en) | Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | |
| US6797842B2 (en) | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | |
| US20070191639A1 (en) | Optically active 1-Aryl-2-fluoro-substituted ethylamine and method for producing same | |
| JPH0635423B2 (en) | Method for producing rimantadine | |
| MXPA01007243A (en) | Method for producing l-phenylephrine hydrochloride | |
| JP4260941B2 (en) | Azetidine-3-ol | |
| WO2024077407A1 (en) | Chiral reducing agent and method for synthesizing chiral nicotine | |
| US20100168385A1 (en) | Process for preparing enantiomerically enriched amino-alcohols | |
| CN113527108A (en) | Process for preparing optically pure 5, 7-difluoro-1, 2,3, 4-tetrahydronaphthalen-2-amine and salts thereof | |
| CN118666704A (en) | Synthesis method of formoterol | |
| JP4212466B2 (en) | Method for producing aralkylamine derivative | |
| EP0564213A2 (en) | Process for the preparation of arylethylamines and substituted arylethylamines | |
| JP2000178239A (en) | Production of n-acetylcyclohexylglycine compound | |
| JPS63141956A (en) | Recovery of catalytic component from carbamic ester solution | |
| JPH04295450A (en) | Method of manufacturing hydrochloride salt of arylalkylamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |